CareDx, Inc (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
17.81
-0.09 (-0.50%)
At close: Nov 26, 2025, 4:00 PM EST
17.40
-0.41 (-2.30%)
After-hours: Nov 26, 2025, 6:24 PM EST
CareDx Revenue
CareDx had revenue of $100.06M in the quarter ending September 30, 2025, with 20.72% growth. This brings the company's revenue in the last twelve months to $358.00M, up 14.46% year-over-year. In the year 2024, CareDx had annual revenue of $333.79M with 19.07% growth.
Revenue (ttm)
$358.00M
Revenue Growth
+14.46%
P/S Ratio
2.69
Revenue / Employee
$550,766
Employees
650
Market Cap
916.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 333.79M | 53.46M | 19.07% |
| Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
| Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
| Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
| Dec 31, 2020 | 192.19M | 65.13M | 51.25% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CDNA News
- 2 days ago - SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation - Business Wire
- 16 days ago - CareDx to Participate in Upcoming Investor Conferences - Business Wire
- 19 days ago - CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025 - Business Wire
- 22 days ago - CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - CareDx Announces Third Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer - Business Wire
- 4 weeks ago - CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure - Business Wire